Toggle light / dark theme

A modular building platform for the most ingenious of robots

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) have developed a system with which they can fabricate miniature robots building block by building block, which function exactly as required.

As one would do with a Lego system, the scientists can randomly combine individual components. The blocks or voxels—which could be described as 3D pixels—are made of different materials: from basic matrix materials that hold up the construction to magnetic components enabling the control of the soft machine. “You can put the individual soft parts together in any way you wish, with no limitations on what you can achieve. In this way, each has an individual magnetisation profile,” says Jiachen Zhang. Together with Ziyu Ren and Wenqi Hu he is first author of the paper entitled “Voxelated three-dimensional miniature magnetic soft machines via multimaterial heterogeneous assembly.” The paper was published in Science Robotics on April 28, 2021.

The project is the result of many previous projects conducted in the Physical Intelligence Department at MPI-IS. For many years, scientists there have been working on magnetically controlled robots for wireless medical device applications at the small scale, from millimeters down to micrometers size. While the state-of-the-art designs they have developed to date have attracted attention around the world, they were limited by the single material with which they were made, which constrained their functionality.

New pumpkin toadlet species found in Brazil

A team of researchers from Universidade Estadual Paulista, Universidade Federal do Mato Grosso do Sul and Projeto Dacnis, São Francisco Xavier and Ubatuba has discovered a new species of pumpkin toadlet. In their paper published on the open-access site PLOS ONE, the group describes their study of pumpkin toadlets in Brazil, how they found the new species and what sets it apart from other pumpkin toadlets.

Pumpkin toadlets are a group of related species of bright orange amphibians. They look like tiny frogs, and most are small enough to sit on a thumbnail—many of them are also poisonous. In this new effort, the researchers were studying pumpkin toadlets living in a heavily forested part of Brazil, just south of the Mantiqueira mountains, along its eastern coast—in the state of São Paulo. To date, several species have been identified. To learn more about them, the researchers traveled to the area multiple times between late 2017 and late 2019, collecting samples. The collecting was made easier through the use of a fluorescent light—some of the bones of the tiny creatures light up right through the skin. In all, the team collected 276 specimens which they took back to their lab for study. Each was given a DNA test to identify its species.

Mechanical engineer offers perspective on the maturation of the field of soft robotics

The field of soft robotics has exploded in the past decade, as ever more researchers seek to make real the potential of these pliant, flexible automata in a variety of realms, including search and rescue, exploration and medicine.

For all the excitement surrounding these new machines, however, UC Santa Barbara mechanical engineering professor Elliot Hawkes wants to ensure that research is more than just a flash in the pan. “Some new, rapidly growing fields never take root, while others become thriving disciplines,” Hawkes said.

To help guarantee the longevity of soft robotics research, Hawkes, whose own robots have garnered interest for their bioinspired and novel locomotion and for the new possibilities they present, offers an approach that moves the field forward. His viewpoint, written with colleagues Carmel Majidi from Carnegie Mellon University and Michael T. Tolley of UC San Diego, is published in the journal Science Robotics.

Young blood to old – where do the answers to aging lie?

“After hopefully demonstrating efficacy through the pilot study, Conboy says that plans are underway for a 200–300 person, placebo-controlled Phase 3 trial to prove the use of the plasma dilution as a technology that innovatively treats co-morbidities of aging.”

This could be the first bridge.


UC Berkeley’s Irina Conboy talks parabiosis, plasma dilution, and why young blood may not hold the all answers.

New Blood Tests Should Show How Long A COVID-19 Vaccine Will Protect You

It took many months and tens of thousands of volunteers to gather the data showing that the current crop of COVID-19 vaccines are safe and effective.

But what if new vaccines are needed to deal with dangerous variants of the coronavirus? Waiting months is not an attractive option.

So researchers are trying to come up with tests that can be performed using a blood sample that will determine not only whether a vaccine will work but also for how long.

MRNA Tech Used in COVID-19 Vaccines Could be Used to Cure HIV, Cancer and More

O,.o What a cure for cancer! o.o


Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.

This has long been thought possible with mRNA technology, but infectious diseases were something of the low-hanging fruit, and the COVID-19 pandemic drove the innovations.

MRNA technology is a way of exploiting the body’s own genetic blueprints. Traditional vaccines used either living or dead viruses to train the immune system to recognize viruses the next time they encounter them. The COVID-19 mRNA vaccines instead use the genetic code for a piece of the virus—the spike protein—and cause the body to generate the spike proteins, which trains the immune system to recognize the virus.

Pfizer Pill for COVID Could Be Ready by End of Year, CEO Says

Pfizer pill to treat COVID symptoms could be ready by year’s end, CEO says.


An oral drug like the one Pfizer is developing could be taken at home and might keep people out of the hospital.

“Particular attention is on the oral because it provides several advantages,” Bourla said. “One of them is that you don’t need to go to the hospital to get the treatment, which is the case with all the injectables so far. You could get it at home, and that could be a game-changer.”

The drug might be effective against the emerging variants, he said. Pfizer is also working on an injectable anti-viral drug.

/* */